Press Releases

VYNE Therapeutics to Present at the Cantor Fitzgerald Investment Conference

September, 20 2021

BRIDGEWATER, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present at the Cantor Fitzgerald Virtual Global Healthcare Conference, to take place September 27th – 30th. The presentation will take the form of a fireside chat, which will be archived here for 90 days. Management will also be available for 1-on-1 meetings with investors. Presentation details  Date:  September 28th Time:  4pm ET Webcast: https://wsw.com/webcast/cantor12/vyne/2115540 About VYNE Therapeutics Inc.VYNE’s mission is to improve the lives of patients by developing proprietary, innovative, and differentiated therapies for…

Read More

VYNE Therapeutics to Present at the H.C. Wainwright Annual Investment Conference

September, 08 2021

BRIDGEWATER, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference to be held virtually from September 13th – 15th. The presentation will take the form of a fireside chat, which will be available on demand here beginning September 13th at 7:00 AM (ET) and archived for 90 days. Management will also be available for 1-on-1 meetings with investors. Date: September 13 Time: On Demand, beginning at 7:00 AM (ET) Webcast: VYNE Fireside Chat For…

Read More

VYNE Therapeutics Reports Second Quarter 2021 Financial Results and Announces New Strategic Direction to Develop Treatments for Immunological and Inflammatory Diseases

August, 12 2021

Company announced license agreement with In4Derm Limited for BETi platform earlier this morning Company has initiated a process to explore a sale or license of its topical minocycline franchise Phase 2a results for FMX114 expected by year end and VYN201 and VYN202 to enter the clinic in 2022 Company has prepaid the entirety of its outstanding debt and expects to significantly reduce operating expenses Conference call and live webcast today at 8:30 am Eastern Time BRIDGEWATER, N.J., Aug. 12, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced financial results for the second quarter…

Read More

VYNE Therapeutics Announces Licensing of BET Inhibitor Platform for Immuno-Inflammatory Conditions with In4Derm Limited

August, 12 2021

VYNE will have exclusive access to a library of new chemical entities VYNE will prioritize initial development efforts on rare skin diseases and major immunology and inflammatory conditions with high unmet needs VYNE expects to enter VYN201 and VYN202 into the clinic in 2022 Further details will be discussed on VYNE’s second quarter earnings call this morning at 8:30am EDT BRIDGEWATER, N.J., Aug. 12, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it has entered into an exclusive license agreement (the “License Agreement”) with In4Derm Limited (“In4Derm”), a spin-out of the University…

Read More

VYNE Therapeutics Announces Approval of AMZEEQ® (Minocycline) and ZILXI® (Minocycline) in Chinese Economic Pilot Zone

August, 02 2021

BRIDGEWATER, N.J., Aug. 02, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that its products AMZEEQ® (minocycline) topical foam, 4%, and ZILXI® (minocycline) topical foam, 1.5%, have been approved for commercial sale in a pilot program in Hainan Boao Lecheng, China. The drug will be sold in the region by Cutia Therapeutics, which licensed the exclusive rights to market AMZEEQ and ZILXI in Greater China. The Boao Lecheng International Medical Tourism Pilot Zone was established with the approval of the Chinese State Council as a unique area in China where certain drugs and…

Read More

VYNE Therapeutics to Report Second Quarter 2021 Financial Results on August 12, 2021

July, 27 2021

BRIDGEWATER, N.J., July 27, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the second quarter ended June 30, 2021, on August 12, 2021, before the market opens. VYNE will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update. Conference Call Details:Thursday, August 12th @ 8:30am Eastern Time Toll Free: 877-256-3294 International: 212-231-2918 Conference ID: 21995997 Webcast: http://public.viavid.com/index.php?id=145705 A replay of the call will be archived on the Company’s website at www.vynetherapeutics.com after the…

Read More